Lannett Co Inc (LCI): Price and Financial Metrics

Lannett Co Inc (LCI)

Today's Latest Price: $7.07 USD

0.19 (-2.62%)

Updated Jul 1 4:10pm

Add LCI to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

LCI Stock Summary

  • Over the past twelve months, LCI has reported earnings growth of -112.7%, putting it ahead of just 14.82% of US stocks in our set.
  • Revenue growth over the past 12 months for Lannett Co Inc comes in at -21.78%, a number that bests just 9.05% of the US stocks we're tracking.
  • Lannett Co Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 34.17%, greater than the shareholder yield of 92.35% of stocks in our set.
  • Stocks that are quantitatively similar to LCI, based on their financial statements, market capitalization, and price volatility, are TLGT, ENT, HL, FCEL, and TEAR.
  • Visit LCI's SEC page to see the company's official filings. To visit the company's web site, go to
LCI Daily Price Range
LCI 52-Week Price Range

LCI Stock Price Chart Technical Analysis Charts

LCI Price/Volume Stats

Current price $7.07 52-week high $15.52
Prev. close $7.26 52-week low $5.46
Day low $7.02 Volume 411,254
Day high $7.55 Avg. volume 688,536
50-day MA $7.80 Dividend yield N/A
200-day MA $8.98 Market Cap 285.28M

Lannett Co Inc (LCI) Company Bio

Lannett Company develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. The company was founded in 1942 and is based in Philadelphia, Pennsylvania.

LCI Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

Below please find a table outlining a discounted cash flow forecast for LCI, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Lannett Co Inc ranked in the 37th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Lannett Co Inc ended up being:

  • Interest coverage, a measure of earnings relative to interest payments, is 0.46 -- which is good for besting merely 24.51% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • 28% of the company's capital comes from equity, which is greater than only 13.42% of stocks in our cash flow based forecasting set.
  • Lannett Co Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Lannett Co Inc? See AMED, HBIO, HAE, BDX, and IQV.

LCI Latest News Stream

Event/TimeNews Detail
Loading, please wait...

LCI Latest Social Stream

Loading social stream, please wait...

View Full LCI Social Stream

Latest LCI News From Around the Web

Below are the latest news stories about Lannett Co Inc that investors may wish to consider to help them evaluate LCI as an investment opportunity.

Is Lannett Company, Inc. (LCI) A Good Stock To Buy?

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]

Yahoo | June 22, 2020

Lannett advances insulin glargine biosimilar

Based on FDA feedback, Lannett Company (LCI) expects to file its U.S. marketing application for biosimilar insulin glargine (Sanofi's Lantus) in calendar year 2022....

Seeking Alpha | June 11, 2020

Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting

Lannett Company, Inc. (NYSE: LCI) today said that representatives from the company spoke with and received guidance from the U.S. Food and Drug Administration (FDA) on the clinical advancement program of its biosimilar insulin glargine partnered product candidate. Insulin glargine is a long-acting insulin used to treat adults with Type 2 diabetes, as well as adults and pediatric patients with Type 1 diabetes, for the control of high blood sugar. Total U.S. sales of the glargine related products, according to IQVIA, were approximately $9.5 billion for the 12 months ending April 2020, although actual biosimilar market values are expected to be lower.

Yahoo | June 11, 2020

Edited Transcript of LCI earnings conference call or presentation 6-May-20 8:30pm GMT

Q3 2020 Lannett Company Inc Earnings Call

Yahoo | May 25, 2020

Results: Lannett Company, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts

It's been a mediocre week for Lannett Company, Inc. (NYSE:LCI) shareholders, with the stock dropping 19% to US$7.58 in...

Yahoo | May 8, 2020

Read More 'LCI' Stories Here

LCI Price Returns

1-mo -5.61%
3-mo 0.14%
6-mo -16.63%
1-year 17.44%
3-year -66.41%
5-year -87.81%
YTD -19.84%
2019 77.82%
2018 -78.62%
2017 5.22%
2016 -45.04%
2015 -6.44%

Continue Researching LCI

Want to see what other sources are saying about Lannett Co Inc's financials and stock price? Try the links below:

Lannett Co Inc (LCI) Stock Price | Nasdaq
Lannett Co Inc (LCI) Stock Quote, History and News - Yahoo Finance
Lannett Co Inc (LCI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9291 seconds.